Significance of paraprotein gap and β2 microglobulins in predialysis Population with multiple myeloma.
Aged
Antineoplastic Agents
/ therapeutic use
Biomarkers
/ blood
Bortezomib
/ therapeutic use
Female
Humans
Male
Multiple Myeloma
/ blood
Paraproteins
/ metabolism
Proteasome Inhibitors
/ therapeutic use
Renal Insufficiency
/ blood
Retrospective Studies
Risk Factors
Time Factors
Treatment Outcome
beta 2-Microglobulin
/ blood
Journal
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
ISSN: 1319-2442
Titre abrégé: Saudi J Kidney Dis Transpl
Pays: Saudi Arabia
ID NLM: 9436968
Informations de publication
Date de publication:
Historique:
entrez:
30
8
2019
pubmed:
30
8
2019
medline:
11
2
2020
Statut:
ppublish
Résumé
Paraprotein gap is sometimes used as a screening tool in some autoimmune diseases, cancers, and screening for latent infections. The increase in the paraprotein gap in these diseases was hypothesized to be the result of increased levels of immunoglobulins, raising the total serum protein without any changes in serum albumin. Our aim was to assess the overall survival using novel chemotherapy, bortezomib compared to traditional ones and to assess if paraprotein gap could be used as a predictor of survival. Finally, we aimed to assess factors that could predict renal response in this population.
Identifiants
pubmed: 31464239
pii: SaudiJKidneyDisTranspl_2019_30_4_825_265458
doi: 10.4103/1319-2442.265458
doi:
Substances chimiques
Antineoplastic Agents
0
B2M protein, human
0
Biomarkers
0
Paraproteins
0
Proteasome Inhibitors
0
beta 2-Microglobulin
0
Bortezomib
69G8BD63PP
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM